Arcutis Biotherapeutics (NASDAQ:ARQT Get Rating) had its target price cut by equities researchers at Truist Financial from $50.00 to $45.00 in a note issued to investors on Wednesday, The Fly reports. The brokerage presently has a buy rating on the stock. Truist Financials target price points to a ...

New INTEGUMENT-1 and INTEGUMENT-2 data show a rapid and significant reduction in itch as early as 24 hours after the first application of roflumilast cream 0.15%Rapid and significant improvements were achieved including individuals reaching a 75% reduction of Eczema Area and Severity Index (EASI-75...

Late breaking session to highlight new data from the INTEGUMENT Phase 3 trials evaluating roflumilast cream in atopic dermatitisNew national survey insights depicting disease burden, path to diagnosis and treatment patterns for seborrheic dermatitisNew clinical safety and efficacy data of topical ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT Get Rating) Research analysts at Cantor Fitzgerald dropped their FY2023 earnings per share estimates for shares of Arcutis Biotherapeutics in a report issued on Wednesday, March 1st. Cantor Fitzgerald analyst L. Chen now forecasts that the company will earn...

Seborrheic dermatitis is an inflammatory skin disease affecting more than 10 million individuals in the United StatesIf approved, roflumilast foam would be the first topical drug for seborrheic dermatitis with a new mechanism of action in over two decadesIn a pivotal Phase 3 trial, 80% of ...